Company Encyclopedia
View More
name
CLOUDR
09955.HK
ClouDr Group Limited provides supplies and software as a service (SaaS) installation to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for patients with chronic condition management. The company’s integrated in-hospital solution offers an AI-driven extensive hospital SaaS to assist doctors in diagnosis and treatment, and to help enhance the doctor education; chronic condition management solution to hospitals, including hospital SaaS and proprietary artificial intelligence of things devices. It also offers pharmacy SaaS, which enables in-store, real-time online consultation, prescription, and risk pooling of outpatient services; and sells chronic condition related drugs based on its data insights in pharmacies, including information on inventory, sales, and shipments of prescription drugs. In addition, the company provides integrated in-and out-of-hospital solutions that connect hospitals and pharmacies; insurance brokerage and advertisement agent services; and sells pharmaceuticals, consumables, medical devices, and miscellaneous, as well as chronic condition related drugs.
166.80 B
09955.HKMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
Health Care DistributorsIndustry
Industry Ranking18/21
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-69.26%E
    • Profit Margin-42.10%E
    • Gross Margin37.08%C
  • Growth ScoreE
    • Revenue YoY-43.70%E
    • Net Profit YoY-236.20%E
    • Total Assets YoY-28.22%E
    • Net Assets YoY-51.54%E
  • Cash ScoreE
    • Cash Flow Margin-237.54%D
    • OCF YoY-43.70%E
  • Operating ScoreB
    • Turnover0.87B
  • Debt ScoreD
    • Gearing Ratio61.92%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ClouDr Group Appoints Hu Yue as Executive Director and Nomination Committee Member

    ClouDr Group Ltd. has appointed Ms. Hu Yue as an executive director and nomination committee member, effective December 27, 2025. The board now includes Mr. Kuang Ming and Ms. Hu Yue as executive directors, along with three independent non-executive directors. This announcement was published by ClouDr Group Ltd. via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    09955
    0.00%
    Reuters·
    HK
    09955
    0.00%

    ClouDr Group Partners with JD Health to Expand Online Sales and Services

    ClouDr Group Ltd. has partnered with JD Health International Inc. to enhance online sales and services for Remifemin® and other P2M pipeline products. This collaboration aims to improve patient access to medications and health management services by utilizing JD Health’s e-commerce platform and ClouDr’s chronic disease management expertise. The partnership is expected to promote high-quality, cost-effective medications to a wider audience.

    Reuters·
    HK
    06618
    +0.52%
    HK
    09955
    0.00%
    Reuters·
    HK
    06618
    +0.52%
    HK
    09955
    0.00%

    ClouDr Group Limited Terminates Transactions and Pursues Legal Action

    ClouDr Group Limited Terminates Transactions and Pursues Legal Action

    Tip Ranks·
    HK
    09955
    0.00%
    Tip Ranks·
    HK
    09955
    0.00%

    "CLOUDR" mid-term loss expands to 549 million RMB

    CLOUDR announced its interim results for the six months ending in June, with revenue recorded at RMB 893 million, a year-on-year decrease of 58%. The loss expanded from RMB 116 million in the same period last year to RMB 549 million, with a loss per share of 92 cents. No dividend is declared

    AASTOCKS·
    HK
    09955
    0.00%
    AASTOCKS·
    HK
    09955
    0.00%

    CLOUDR 2025 Mid-term Performance Briefing: Operating Cash Flow Turns Positive for the First Time, P2M Business Grows by 142.1%

    On August 27th, CLOUDR released its semi-annual performance: same-caliber revenue of 890 million yuan, a year-on-year increase of 20.3%; adjusted gross margin increased by 29.3 percentage points year-on-year to 49.9%, and net loss narrowed by 23.3%; operating cash flow turned positive historically, with a net inflow of 28.65 million yuan (compared to a net outflow of 195 million yuan in the same period last year). Revenue from P2M solutions was 260 million yuan with profitability, a year-on-year increase of 142.1%; six core products have been launched, and eight new products are queued for launch. The AI dual model (ClouD GPT/DTx) has completed the data-monetization closed loop, and the gestational diabetes solution has been published in an international journal; the company's SaaS has covered over 2,700 hospitals and nearly 270,000 pharmacies. Management stated that they will accelerate the commercialization of P2M and consolidate their leading position in chronic disease digitalization

    Zhitong·
    HK
    09955
    0.00%
    Zhitong·
    HK
    09955
    0.00%
    © 2025 Longbridge｜Disclaimer